StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit Suisse
September 21, 2017 6:26 AM
Credit Suisse analyst Alethia Young raised her price target on Alnylam Pharmaceuticals ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Alnylam Pharmaceuticals (ALNY) PT Raised to $134 at BMO Capital; Makes Case for $165 Upside Scenario
September 21, 2017 3:40 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $101 at Morgan Stanley
September 21, 2017 8:37 AM
Alnylam Pharmaceuticals (ALNY) PT Raised to $135 at Bernstein
September 21, 2017 7:23 AM
UPDATE: Alnylam Pharmaceuticals (ALNY) PT Raised to $146 at Ladenburg Thalmann
September 21, 2017 7:04 AM
Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company
September 20, 2017 3:20 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP Securities
September 20, 2017 2:14 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at Stifel
September 20, 2017 1:41 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'
September 20, 2017 12:36 PM
Arbutus Biopharma (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY) Reports Positive Phase 3 Results for LNP-Enabled Patisiran Program
September 20, 2017 12:25 PM
Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
September 20, 2017 12:22 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $116 at Piper Jaffray
September 20, 2017 11:39 AM
Alnylam Pharma (ALNY) Adds to Gains; Shares up 40%
September 20, 2017 10:23 AM
Royalty Stream to Arbutus Biopharma (ABUS) from Alnylam (ALNY) 'Could be Significant' - Wedbush
September 20, 2017 10:19 AM
Arbutus Biopharma (ABUS) Gains Sharply Following Alnylam Trial Success
September 20, 2017 10:12 AM
Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints
September 20, 2017 7:02 AM
Sanofi (SNY) and Alnylam (ALNY) APOLLO Phase 3 Study of Patisiran in hATTR Meets Primary, Secondary Endpoints
September 20, 2017 7:01 AM
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
September 20, 2017 7:00 AM
